Business Wire

NY-IFF

25.6.2020 14:02:08 CEST | Business Wire | Press release

Share
IFF Embraces “Do More Good” in 2019 Sustainability Report

Regulatory News:

IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, today published its 2019 Sustainability Report, “Do More Good.” The title references a pillar of the Company’s purpose, To redefine how we live in and care for the resources of our world , which was launched last year as part of its most significant rebrand in 40 years. The report highlights IFF’s sustainability accomplishments throughout the business and covers the Company’s achievements in leveraging sustainable practices within its global footprint.

Andreas Fibig, IFF Chairman and CEO, said: “The leadership position that we have taken in sustainability is a reflection of the passion to do more good that’s been embraced by our people everywhere at IFF. We credit our customers, partners and suppliers for the incredible and productive alliances we have forged together in the service of sustainability. This is not a journey we can – or want - to take alone. It requires the energy and commitment of like-minded allies willing to challenge the status quo – and each other – to do what is ultimately best for people and planet.”

The 2019 report highlights include:

  1. IFF’s new purpose and Vision 2021 strategy, reflecting the importance of sustainability as a way of doing business at IFF
  2. External recognitions for IFF’s sustainability leadership, such as Barron’s, FTSE4Good, RobecoSAM Industry Mover award, Euronext Vigeo, and CDP A list
  3. Continued commitment to climate action, as demonstrated by the opening of the Union Beach, New Jersey solar array, the signing of the U.N. Business Ambition for 1.5°C: Our Only Future pledge, and strong progress against its environmental goals for greenhouse gas emission reductions (including a decrease in absolute emissions of 5.7% from prior year), and zero waste to landfill and water stewardship
  4. Strengthening of IFF’s responsible sourcing program and natural ingredient supply chains through new certifications, as well as by accelerating industry-leading blockchain technology as a tool for ensuring ingredient traceability
  5. Achieving an industry breakthrough in circular design and transparency with Henry Rose, a line of fine fragrances founded by actress Michelle Pfeiffer and created to the strictest environmental standards as defined by the Environmental Working Group and the Cradle to Cradle Products Innovation Institute
  6. External recognitions and certifications for IFF’s diversity & inclusion leadership, such as DiversityInc., Human Rights Campaign, EDGE, and the signing of the U.N. Global LGBTI Standards of Conduct for Business and the U.N. Women’s Empowerment Principles
  7. Accelerated the inclusion of legacy Frutarom data, where available, in response to stakeholder interest and to prepare for the anticipated merger with DuPont’s Nutrition & Biosciences business. This process included a significant data collection and training effort for more than 60 facilities in 27 countries.

Dr. Greg Yep, IFF’s Chief Scientific & Sustainability Officer, said, “IFF’s sustainability accomplishments are considerable and meaningful and I must thank our global network of green teams who are empowered to drive change for IFF and our communities. As pleased as we are with our results, from external recognitions to meeting and exceeding our goals, I know I speak for all of IFF when I confirm our commitment to continually improve and drive better outcomes, and always seeks ways to live up to our purpose and do more good.”

To read IFF’s 2019 Sustainability Report, visit iff.com/sustain and use #SustainxIFF to follow the conversation on its social channels.

# # #

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye